The efficacy of telmisartan compared with perindopril in patients with mild-to-moderate hypertension

• Published in: International journal of clinical practice (Esher) Vol. 58; no. s145; pp. 50 - 54
• Main Authors: Nalbantgil, I, Nalbantgil, S, Ozerkan, F, Yilmaz, H, Gürgün, C, Zoghi, M, Aytimur, M, Onder, R
• Format: Journal Article
• Language: English
• Published: Oxford, UK Blackwell Publishing Ltd 01.12.2004; Hindawi Limited
• Subjects: Adult; Aged; angiotensin II receptor blocker; Angiotensin II Type 1 Receptor Blockers - administration & dosage; Angiotensin II Type 1 Receptor Blockers - adverse effects; angiotensin-converting enzyme inhibitor; Angiotensin-Converting Enzyme Inhibitors - administration & dosage; Angiotensin-Converting Enzyme Inhibitors - adverse effects; Antihypertensive Agents - administration & dosage; Antihypertensive Agents - adverse effects; antihypertensives; Benzimidazoles - administration & dosage; Benzimidazoles - adverse effects; Benzoates - administration & dosage; Benzoates - adverse effects; Blood Pressure - physiology; Double-Blind Method; Female; Humans; hypertension; Hypertension - drug therapy; Hypertension - physiopathology; Male; Middle Aged; perindopril; Perindopril - administration & dosage; Perindopril - adverse effects; Single-Blind Method; Telmisartan
• ISSN: 1368-5031; 1368-504X; 1742-1241
• DOI: 10.1111/j.1742-1241.2004.00411.x

Summary In this study, efficacy of the angiotensin II type 1 receptor blocker telmisartan given as monotherapy was compared with that of perindopril monotherapy in patients with mild‐to‐moderate hypertension. After a 2‐week, single‐blind, placebo run‐in period, 60 patients were randomised to double‐blind, once‐daily treatment with telmisartan 80 mg or perindopril 4 mg for 6 weeks. Clinic and ambulatory blood pressure measurements and clinical laboratory evaluation were performed at the end of the placebo run‐in and active treatment phases. Both telmisartan and perindopril significantly (p < 0.0001) reduced clinic systolic blood pressure (SBP) and diastolic blood pressure (DBP) compared with baseline values. Also, both drugs significantly (p < 0.0001) reduced 24‐h mean ambulatory SBP and DBP compared with baseline. Comparison of the mean hourly antihypertensive activities showed that the reduction in mean ambulatory DBP for the last 8 h of the dosing interval was significantly greater (p < 0.05) in telmisartan‐treated patients. A 24‐h mean DBP of <85 mmHg was observed in 66.6% of the telmisartan‐treated patients but in only 46.6% of the perindopril‐treated patients (p < 0.05). It is concluded that telmisartan and perindopril both produce significant reductions in clinic SBP and DBP, but the mean reduction in ambulatory DBP during the last 8 h of the dosing interval is greater in patients treated with telmisartan.